CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Price, Quote, News and Overview
NASDAQ:CYCC - Nasdaq - US23254L8019 - Common Stock - Currency: USD
CYCC Quote, Performance and Key Statistics
11.66
-1.41 (-10.79%)
The current stock price of CYCC is 11.66 USD. In the past month the price increased by 128.02%. In the past year, price decreased by -97.14%.
CYCC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 326.52B | ||
| AMGN | AMGEN INC | 14.25 | 159.09B | ||
| GILD | GILEAD SCIENCES INC | 13.99 | 134.69B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 117.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.31 | 58.90B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.79B | ||
| ARGX | ARGENX SE - ADR | 98.46 | 34.57B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.47 | 31.59B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.18B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.56B | ||
| INSM | INSMED INC | N/A | 19.50B | ||
| NTRA | NATERA INC | N/A | 19.20B |
Related stock screener links
About CYCC
Company Profile
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
Company Info
CYCLACEL PHARMACEUTICALS INC
200 Connell Dr Ste 1500
Berkeley Heights NEW JERSEY 07922 US
CEO: Spiro Rombotis
Employees: 0
Phone: 19085177330
CYCLACEL PHARMACEUTICALS INC / CYCC FAQ
What is the stock price of CYCLACEL PHARMACEUTICALS INC today?
The current stock price of CYCC is 11.66 USD. The price decreased by -10.79% in the last trading session.
What is the ticker symbol for CYCLACEL PHARMACEUTICALS INC stock?
The exchange symbol of CYCLACEL PHARMACEUTICALS INC is CYCC and it is listed on the Nasdaq exchange.
On which exchange is CYCC stock listed?
CYCC stock is listed on the Nasdaq exchange.
What is CYCLACEL PHARMACEUTICALS INC worth?
CYCLACEL PHARMACEUTICALS INC (CYCC) has a market capitalization of 18.42M USD. This makes CYCC a Nano Cap stock.
How many employees does CYCLACEL PHARMACEUTICALS INC have?
CYCLACEL PHARMACEUTICALS INC (CYCC) currently has 0 employees.
What are the support and resistance levels for CYCLACEL PHARMACEUTICALS INC (CYCC) stock?
CYCLACEL PHARMACEUTICALS INC (CYCC) has a resistance level at 13.08. Check the full technical report for a detailed analysis of CYCC support and resistance levels.
Is CYCLACEL PHARMACEUTICALS INC (CYCC) expected to grow?
The Revenue of CYCLACEL PHARMACEUTICALS INC (CYCC) is expected to grow by 88.68% in the next year. Check the estimates tab for more information on the CYCC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CYCLACEL PHARMACEUTICALS INC (CYCC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CYCC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CYCC, evaluating the profitability, health, valuation and growth aspects
- CYCLACEL PHARMACEUTICALS INC (CYCC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYCLACEL PHARMACEUTICALS INC (CYCC) Sales and EPS estimates to see what analysts future expectations are.
- CYCLACEL PHARMACEUTICALS INC (CYCC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYCLACEL PHARMACEUTICALS INC (CYCC) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Chart to make your own analysis
- CYCLACEL PHARMACEUTICALS INC (CYCC) Latest news and press-releases to stay up to date.
Does CYCLACEL PHARMACEUTICALS INC (CYCC) stock pay dividends?
CYCC does not pay a dividend.
When does CYCLACEL PHARMACEUTICALS INC (CYCC) report earnings?
CYCLACEL PHARMACEUTICALS INC (CYCC) will report earnings on 2025-08-12.
What is the Price/Earnings (PE) ratio of CYCLACEL PHARMACEUTICALS INC (CYCC)?
CYCLACEL PHARMACEUTICALS INC (CYCC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-19.58).
CYCC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CYCC. When comparing the yearly performance of all stocks, CYCC is a bad performer in the overall market: 99.8% of all stocks are doing better.
CYCC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYCC. While CYCC seems to be doing ok healthwise, there are quite some concerns on its profitability.
CYCC Financial Highlights
Over the last trailing twelve months CYCC reported a non-GAAP Earnings per Share(EPS) of -19.58. The EPS increased by 94.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -223.54% | ||
| ROE | -272.6% | ||
| Debt/Equity | 0 |
CYCC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to CYCC. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 39.49% and a revenue growth 88.68% for CYCC